Additional file 1 of Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial

Andreas Meinitzer (412847); Dirk von Lewinski (3142926); Ewald Kolesnik (5450903); Faisal Aziz (676597); Harald Mangge (624649); Harald Sourij (239385); Markus Hermann (1569799); Norbert J. Tripolt (16627986); Pero Curcic (16627989); Peter N. Pferschy (5450906)

Additional file 1 of Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial

Authors: Andreas Meinitzer (412847)
Dirk von Lewinski (3142926)
Ewald Kolesnik (5450903)
Faisal Aziz (676597)
Harald Mangge (624649)
Harald Sourij (239385)
Markus Hermann (1569799)
Norbert J. Tripolt (16627986)
Pero Curcic (16627989)
Peter N. Pferschy (5450906)
Publication date: 20 July 2023
Publisher
Doi

Abstract

Additional file 1: Fig. S1. Distribution of untransformed TMAO concentration (μmol/L) by treatment groups at A—baseline, B—6 weeks, and C—26 weeks. Table S1. LDL-C levels over visits by treatment groups

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/23722...

Last time updated on 22/07/2023